Novavax(NVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVAX Novavax

Trading 04-07 15:46:29 EDT

6.48

+0.24

+3.85%

High6.61	Low5.80	Vol5.89M
Open5.83	D1 Closing6.24	Amplitude12.98%
Mkt Cap1.04B	Tradable Cap878.54M	Total Shares160.84M
T/O37.09M	T/O Rate4.34%	Tradable Shares135.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"NVAX","market":"US","secType":"STK","nameCN":"Novavax","latestPrice":6.48,"timestamp":1744055188587,"preClose":6.24,"halted":0,"volume":5885819,"delay":0,"floatShares":135576570,"shares":160844197,"eps":-1.232006,"marketStatus":"Trading","change":0.24,"latestTime":"04-07 15:46:29 EDT","open":5.83,"high":6.61,"low":5.8,"amount":37091061.707918696,"amplitude":0.129808,"askPrice":6.48,"askSize":13,"bidPrice":6.47,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.232006,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1744056000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":6.24,"preHourTrading":{"tag":"盘前","latestPrice":5.82,"preClose":6.24,"latestTime":"09:28 EDT","volume":69972,"amount":416402.182476,"timestamp":1744032508849},"postHourTrading":{"tag":"盘后","latestPrice":6.19,"preClose":6.24,"latestTime":"19:59 EDT","volume":89874,"amount":560294.8126,"timestamp":1743811183209},"volumeRatio":0.840279,"impliedVol":1.044,"impliedVolPercentile":0.3665},"requestUrl":"/m/hq/s/NVAX/wiki","defaultTab":"wiki","newsList":[{"id":"2525099306","title":"Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2525099306","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525099306?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 15:27","pubTimestamp":1744010820,"startTime":"0","endTime":"0","summary":"Novavax NVAX shares soared 11.4% in the last trading session to close at $6.24. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 28.8% loss over the past four weeks.The rise in Novavax’s shares can be attributed to the stock price recovery after it fell for 8 consecutive sessions. Despite the FDA’s delay in approving the company’s protein-based COVID-19 vaccine, the upside in NVAX’s stock suggests that investors perceive a favorable decision from the agency.This vaccine maker is expected to post quarterly loss of $0.43 per share in its upcoming report, which represents a year-over-year change of +59.1%. Revenues are expected to be $72.27 million, down 23% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price mo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novavax-nvax-soars-11-4-072700082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVAX","BK4588","BK4139","BK4547","TVTX","BK4568","BK4585"],"gpt_icon":0},{"id":"2525737331","title":"The FDA Is Being Gutted. 'People Are Going to Die.' -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2525737331","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525737331?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 04:00","pubTimestamp":1743796800,"startTime":"0","endTime":"0","summary":"When Vera Rosenthal left work at the offices of Food and Drug Administration a week ago, she made sure to take home her Dr. Anthony Fauci bobblehead doll.Rosenthal had a hunch layoffs were on the way. \"I was not letting them keep my Fauci bobblehead,\" she says.Massive layoffs passed like a scythe through the FDA this week, part of health secretary Robert F. Kennedy Jr.'s plan to cut as many as 10,000 inside the U.S. Department of Health and Human Services, including 3,500 at FDA.FDA deadlines, called PDUFA dates, are set under agreement between the industry and the FDA, and aren't often missed. Last year, the FDA division responsible for approving new drugs hit its PDUFA goal dates 94% of the time.\"It's possible that RFK wanted to raise additional questions about a vaccine application,\" says David Risinger, an analyst at Leerink Partners. \"It's also possible that it may be a sign that PDUFA dates may not be met, given the turmoil at FDA.\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4585","BK4568","BK4588","NVAX","BK4139"],"gpt_icon":0},{"id":"2524242249","title":"Novavax’s Regulatory Uncertainty and Market Potential: Hold Rating Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2524242249","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524242249?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 08:55","pubTimestamp":1743728116,"startTime":"0","endTime":"0","summary":"Steve Scala, an analyst from TD Cowen, maintained the Hold rating on Novavax (NVAX – Research Report). The associated price target remains the same...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/novavaxs-regulatory-uncertainty-and-market-potential-hold-rating-maintained?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/novavaxs-regulatory-uncertainty-and-market-potential-hold-rating-maintained?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVAX"],"gpt_icon":0},{"id":"2524211632","title":"Novavax Inc. Stock Underperforms Thursday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2524211632","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524211632?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 05:26","pubTimestamp":1743715560,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Novavax Inc.  slid 6.35% to $5.60 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index  falling 5.97% to 16,550.61 and Dow Jones Industrial Average  falling 3.98% to 40,545.93.This was the stock's eighth consecutive day of losses.Novavax Inc. closed 76.53% short of its 52-week high of $23.86, which the company achieved on June 6th.The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson  rose 2.87% to $159.82, Pfizer Inc.  fell 1.66% to $24.29, and Merck & Co. Inc.  fell 0.24% to $86.39.Trading volume  eclipsed its 50-day average volume of 4.2 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 3, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Stre","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX"],"gpt_icon":0},{"id":"2524290290","title":"FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS","url":"https://stock-news.laohu8.com/highlight/detail?id=2524290290","media":"Yahoo Finance","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524290290?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 03:39","pubTimestamp":1743709147,"startTime":"0","endTime":"0","summary":"The US Food and Drug Administration was supposed to make a final decision about whether or not to approve Novavax's  COVID-19 vaccine this week, but that deadline has passed with no clarity on when the decision will move forward again.The vaccine remains available under the emergency use authorization  it received during the pandemic.But the delayed decision and missed deadline, first reported by the Wall Street Journal, could signal further pain ahead for the pharmaceutical and biotech sectors, especially vaccine companies: a fear that has been mounting in the wake of mass layoffs at the health agencies this week.Education Secretary nominee Linda McMahon , and U.S. Health and Human Services Secretary Robert F. . Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-delay-on-novavax-vaccine-approval-could-be-bellwether-for-vaccine-sector-bofas-193907654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["JNJ","BK4547","IE00B7SZLL34.SGD","LU1674673428.USD","IE00B19Z3B42.SGD","LU1778281490.HKD","L","LU0345770308.USD","IE00BJT1NW94.SGD","LU0203347892.USD","LU1032466523.USD","LU1674673691.USD","BK4532","LU0345770993.USD","LU2129689605.HKD","LU2505996509.AUD","NVAX","LU0289739699.SGD","IE00B2B36J28.USD","LU1267930813.SGD","LU1032955483.USD","BK4501","LU0053666078.USD","LU1057294990.SGD","IE00BDGV0183.EUR","LU0345769631.USD","LU2129689431.USD","LU2468319806.SGD","BK4592","IE00BVYPNV92.GBP","LU0058720904.USD","LU0098860793.USD","IE00B4R5TH58.HKD","LU1244550221.USD","LU1929549753.HKD","SNY","LU2430703095.HKD","MRNA","BK4548","LU1023059063.AUD","LU1066053197.SGD","LU1280957306.USD","IE00BJJMRZ35.SGD","LU1066051225.USD","LU2129689514.USD","LU1506573853.SGD","LU1261432733.SGD","LU1066051811.HKD","LU0795875169.SGD","LU2602419157.SGD"],"gpt_icon":1},{"id":"2524426237","title":"Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2524426237","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524426237?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 23:13","pubTimestamp":1743693211,"startTime":"0","endTime":"0","summary":"Small to mid-cap biotechnology companies are likely to see macro headwinds extend through the year, with tariff concerns and turnover at the US Food and Drug Administration further fueling near-term uncertainty, BofA Securities said in a Thursday note.BofA Securities said an example of the FDA turnover's impact is the pause on the review of Novavax's  Nuvaxovid COVID-19 vaccine, but the magnitude of recent layovers at the FDA \"could take time to materialize.\"The investment firm also said that \"headline risk\" continues to be a headwind but could decrease since pharmaceuticals are being exempted from US President Donald Trump's reciprocal tariffs, which should provide \"near-term reprieve for the sector.\" The analysts said many of the small to mid-cap biotechnology firms have \"little exposure\" to tariffs as about 80% of them are \"pre-commercial.\"BofA Securities said Agios Pharmaceuticals , Janux Therapeutics , CRISPR Therapeutics , and Revolution Medicines  are its top small to mid-cap bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","LU1861559042.SGD","RVMD","BK4585","LU1861558580.USD","AGIO","BK4547","BK4611","BK4568","BK4139","NVAX","CRSP","BK4588","JANX","BK4556"],"gpt_icon":0},{"id":"1121702600","title":"Pharma Stocks Survive Market Rout on Tariff Exemption, but Uncertainty Continues","url":"https://stock-news.laohu8.com/highlight/detail?id=1121702600","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121702600?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 22:00","pubTimestamp":1743688825,"startTime":"0","endTime":"0","summary":"LONDON/BENGALURU April 3 (Reuters) - Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from reciprocal tariffs, but executives and ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","JNJ","REGN","VXRT","SNY","MRNA","AZN","MRK","OCGN","VERU","LLY","BNTX","ABT","IBIO","GILD","NVAX","PFE","GSK"],"gpt_icon":1},{"id":"1115825291","title":"Stock Track | Novavax Plummets 9.78% as FDA Misses Crucial COVID-19 Vaccine Decision Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=1115825291","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115825291?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 21:38","pubTimestamp":1743687489,"startTime":"0","endTime":"0","summary":"Novavax  shares plunged 9.78% in pre-market trading on Thursday, following news that the U.S. Food and Drug Administration  has missed a critical deadline regarding the company's COVID-19 vaccine. This sharp decline reflects growing investor concerns about potential delays in the vaccine's approval process.The situation underscores the challenges faced by pharmaceutical companies in the highly regulated and time-sensitive field of vaccine development. For Novavax, which has been working diligent","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NVAX"],"gpt_icon":0},{"id":"1167005446","title":"Stock Track | Novavax Plunges 5.85% Pre-market as FDA Misses Deadline on COVID-19 Vaccine Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=1167005446","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167005446?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 19:42","pubTimestamp":1743680572,"startTime":"0","endTime":"0","summary":"Shares of Novavax  tumbled 5.85% in pre-market trading on Thursday, following news that the U.S. Food and Drug Administration  has missed a crucial deadline regarding the company's COVID-19 vaccine. This development has sparked concerns among investors about potential delays in the vaccine's approval process.According to reports, the FDA failed to make a key decision regarding Novavax's COVID-19 vaccine within the expected timeframe. This missed deadline comes just days after the FDA's vaccine c","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NVAX"],"gpt_icon":0},{"id":"1182238375","title":"Stock Track | Novavax Plunges 5.85% in Pre-market as FDA Misses Key Vaccine Decision Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=1182238375","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182238375?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 19:42","pubTimestamp":1743680572,"startTime":"0","endTime":"0","summary":"Shares of Novavax  tumbled 5.85% in pre-market trading on Thursday, following news that the U.S. Food and Drug Administration  has missed a crucial deadline regarding the company's COVID-19 vaccine.According to reports, the FDA failed to make a key decision concerning Novavax's COVID-19 vaccine within the expected timeframe. This delay comes just days after the FDA's vaccine chief was unexpectedly removed from their position, adding another layer of uncertainty to the situation.The missed deadli","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Novavax Plunges 5.85% in Pre-market as FDA Misses Key Vaccine Decision Deadline","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NVAX"],"gpt_icon":0},{"id":"2524405286","title":"PRESS DIGEST - Wall Street Journal - April 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2524405286","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524405286?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 13:14","pubTimestamp":1743657273,"startTime":"0","endTime":"0","summary":"PRESS DIGEST - Wall Street Journal - April 3April 3 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accura","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nL3N3QH0GI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525689.USD","LU1868837136.USD","APP","LU0823434583.USD","LU1868836757.USD","UNH","LU0949170772.SGD","LU0689472784.USD","NVAX","GB00B4LPDJ14.GBP","LU1035773651.USD","LU1291159041.SGD","LU2430703251.USD","LU0342679015.USD","LU0786609619.USD","LU0345770308.USD","LU0211331839.USD","META","LU2430703178.SGD","LU2430703095.HKD","LU1153585028.USD","LU0251132253.USD","LU1720051108.HKD","LU1732799900.SGD","LU2264538146.SGD","LU1564329032.USD","CVS","LU2324357040.USD","LU0006061336.USD","LU0672654240.SGD","LU0348723411.USD","LU0158827948.USD","LU0820562030.AUD","LU1815336760.USD","SG9999018857.SGD","LU0234570918.USD","LU0690374961.EUR","LU1629891620.HKD","LU0719512351.SGD","LU2106854487.HKD","LU2468319806.SGD","BK4539","IE00BJJMRX11.SGD","LU0070302665.USD","LU0082616367.USD","LU0211326755.USD","CI","IE00BJJMRY28.SGD","LU1674673428.USD","LU1037948897.HKD"],"gpt_icon":1},{"id":"2524423475","title":"Novavax (NVAX) Stock Sinks As Market Gains: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2524423475","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524423475?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 05:45","pubTimestamp":1743630315,"startTime":"0","endTime":"0","summary":"In the latest trading session, Novavax  closed at $5.98, marking a -0.33% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.67%. At the same time, the Dow added 0.56%, and the tech-heavy Nasdaq gained 0.87%.The vaccine maker's shares have seen a decrease of 21.88% over the last month, not keeping up with the Medical sector's loss of 5.32% and the S&P 500's loss of 5.28%.Analysts and investors alike will be keeping a close eye on the performance of Novavax in its upcoming earnings disclosure. The company is expected to report EPS of -$0.43, up 59.05% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $72.27 million, indicating a 23.01% decline compared to the corresponding quarter of the prior year.For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.11 per share and a revenue of $536.58 million, signifying shifts of +91.06% and -21.34%, respectively, from the las","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novavax-nvax-stock-sinks-market-214515921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","BK4139","BK4588","BK4585","BK4547","NVAX"],"gpt_icon":1},{"id":"2524444615","title":"Health Care Up as Biotech Rebounds -- Health Care Roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2524444615","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524444615?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 05:26","pubTimestamp":1743629160,"startTime":"0","endTime":"0","summary":"Health care companies rose as traders rotated back into high-risk biotech firms.Federal drug regulators missed the deadline for making a key decision regarding a Covid-19 vaccine from Novavax, days after the Food and Drug Administration's vaccine chief was pushed out.Novavax ticked up, but remained deep in the red for the year to date. The Federal Trade Commission's lawsuit against three large pharmacy-benefit managers over insulin prices -- Cigna's Express Scripts, UnitedHealth Group's Optum Rx and CVS Health's CVS Caremark -- is on hold after President Trump fired two of the agency's commissioners.Planned Parenthood is closing clinics and facing more financial strains as Republican control of Washington opens new avenues for weakening the abortion provider.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","US12M.BOND","US5Y.BOND","US7Y.BOND","US6M.BOND","US3Y.BOND","BK4588","US30Y.BOND","BK4585","BK4547","NVAX","US10Y.BOND","US2Y.BOND"],"gpt_icon":0},{"id":"2524443013","title":"Update: Novavax Awaits Decision on Full Approval of Covid Vaccine After FDA Misses Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2524443013","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524443013?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 04:01","pubTimestamp":1743624098,"startTime":"0","endTime":"0","summary":"Novavax  said Wednesday it is still awaiting a decision from the US Food and Drug Administration on its biologics license application for its Covid vaccine.The vaccine approval is in limbo after the FDA missed a deadline, but a decision could be any day, The Wall Street Journal reported earlier.The FDA previously allowed emergency use of Novavax's vaccine and the agency's decision would have determined whether to grant the vaccine a full approval, the report said, citing sources.FDA did not immediately respond to requests for comment from MT Newswires.NVAX shares were up 3% in recent trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NVAX","BK4547","BK4568","BK4588","BK4585"],"gpt_icon":0},{"id":"2524767448","title":"BRIEF-Novavax Can Confirm That April 1, Was U.S FDA’S PDUFA Date For BLA Seeking Approval Of Our Covid-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2524767448","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524767448?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 03:29","pubTimestamp":1743622141,"startTime":"0","endTime":"0","summary":"BRIEF-Novavax Can Confirm That April 1, Was U.S FDA’S PDUFA Date For BLA Seeking Approval Of Our Covid-19 VaccineApril 2  - Novavax Inc NVAX.O:NOVAVAX: CAN CONFIRM THAT APRIL 1, WAS U.S. FDA’S PDUFA DATE FOR BLA SEEKING APPROVAL OF OUR COVID-19 VACCINE - STATEMENTNOVAVAX INC: AS OF TUESDAY, APRIL 1,BELIEVE THAT OUR BLA IS READY FOR APPROVALNOVAVAX INC: HAVE NOT YET RECEIVED OFFICIAL DECISION FROM U.S. FDAFurther company coverage: NVAX.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG1BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","BK4547","NVAX","BK4568"],"gpt_icon":0},{"id":"2524941753","title":"Novavax Inc: Have Not yet Received Official Decision From U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2524941753","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524941753?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 02:09","pubTimestamp":1743617395,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG1BF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4568","BK4585","BK4547","NVAX","BK4139"],"gpt_icon":0},{"id":"2524417323","title":"Novavax: Can Confirm That April 1, Was U.S. FDA’s Pdufa Date for Bla Seeking Approval of Our Covid-19 Vaccine - Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2524417323","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524417323?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 02:09","pubTimestamp":1743617395,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG1BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVAX","BK4139","BK4585","BK4547","BK4588","BK4568"],"gpt_icon":0},{"id":"2524175334","title":"Novavax Inc: as of Tuesday, April 1,Believe That Our Bla Is Ready for Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2524175334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524175334?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 02:09","pubTimestamp":1743617395,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG1BF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","BK4547","NVAX","BK4588","BK4568"],"gpt_icon":0},{"id":"2524414898","title":"FDA Misses Deadline for Granting Full Approval for Novavax's Covid-19 Vaccine, Sources Say -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2524414898","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524414898?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 01:20","pubTimestamp":1743614400,"startTime":"0","endTime":"0","summary":"Federal drug regulators have missed the deadline for making a key decision regarding a Covid-19 vaccine from Novavax, days after the Food and Drug Administration's vaccine chief was pushed out.The agency was set to give full approval to Novavax's shot, but senior leaders at the agency are now sitting on the decision and have said the Novavax application needed more data and was unlikely to be approved soon, people familiar with the matter said.The FDA has allowed emergency use of Novavax's Covid-19 vaccine. It set an April 1 deadline for a decision on whether to grant a normal, full approval, the people said.The decision would have cleared the vaccine's continuing use though the pandemic emergency has passed. The FDA gave full approval to Covid-19 shots from Pfizer and its partner BioNTech and from Moderna in 2021 and 2022, respectively.Novavax said it is \"continuing to communicate with the FDA and dialogue to ensure they have all the information required to complete our\" application.N","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","NVAX","BK4534","LU0456855351.SGD","LU1023059063.AUD","LU0321505439.SGD","SG9999002232.USD","IE00BBT3K403.USD","LU1883839398.USD","LU1894683264.USD","IE00BLSP4452.SGD","LU1066053197.SGD","SG9999001176.SGD","BK4551","SGXZ57979304.SGD","SG9999003800.SGD","LU0225771236.USD","BK4585","BK4007","BK4588","IE0002270589.USD","LU0122379950.USD","LU0170899867.USD","BK4568","LU0306806265.USD","BNTX","SG9999001176.USD","SG9999011175.SGD","LU1057294990.SGD","LU0985481810.HKD","LU1066051498.USD","BK4533","BK4547","LU0234572021.USD","BK4581","LU0289739699.SGD","SG9999013999.USD","SG9999002224.SGD","LU0321505868.SGD","LU1894683348.USD","BK4550","BK4548","BK4599","IE00B19Z3581.USD","LU0306807586.USD","IE00B19Z3B42.SGD","BK4139","IE000M9KFDE8.USD","BK4592"],"gpt_icon":1},{"id":"2524419756","title":"Market Chatter: US FDA Misses Deadline for Full Approval of Novavax's Covid-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2524419756","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524419756?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 00:51","pubTimestamp":1743612676,"startTime":"0","endTime":"0","summary":"A US approval of Novavax's  COVID-19 vaccine is in limbo after the Food and Drug Administration missed a deadline for a full approval of the treatment, The Wall Street Journal reported Wednesday.The FDA previously allowed emergency use of Novavax's vaccine and the agency's decision would have determined whether to grant the vaccine a normal, full approval, the report said, citing people familiar with the matter.Novavax's application is still reportedly pending and could be approved by the agency at any time, the sources said.Novavax and the FDA did not immediately respond to requests for comment from MT Newswires.NVAX shares were up 3% in recent trading.Price: 6.18, Change: +0.18, Percent Change: +3.02","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","BK4139","BK4568","BNTX","BK4551","BK4585","BK4535","BK4588","BK4547","NVAX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novavax.com","stockEarnings":[{"period":"1week","weight":-0.1086},{"period":"1month","weight":-0.2091},{"period":"3month","weight":-0.2949},{"period":"6month","weight":-0.5415},{"period":"1year","weight":0.4054},{"period":"ytd","weight":-0.2239}],"compareEarnings":[{"period":"1week","weight":-0.0907},{"period":"1month","weight":-0.1334},{"period":"3month","weight":-0.1464},{"period":"6month","weight":-0.1182},{"period":"1year","weight":-0.0152},{"period":"ytd","weight":-0.1379}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.101177},{"month":2,"riseRate":0.566667,"avgChangeRate":0.039349},{"month":3,"riseRate":0.266667,"avgChangeRate":-0.040904},{"month":4,"riseRate":0.433333,"avgChangeRate":0.006794},{"month":5,"riseRate":0.517241,"avgChangeRate":0.126888},{"month":6,"riseRate":0.517241,"avgChangeRate":0.09837},{"month":7,"riseRate":0.551724,"avgChangeRate":0.018176},{"month":8,"riseRate":0.517241,"avgChangeRate":0.037008},{"month":9,"riseRate":0.482759,"avgChangeRate":-0.043221},{"month":10,"riseRate":0.310345,"avgChangeRate":0.029378},{"month":11,"riseRate":0.344828,"avgChangeRate":0.002076},{"month":12,"riseRate":0.37931,"avgChangeRate":-0.038326}],"exchange":"NASDAQ","name":"Novavax","nameEN":"Novavax"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Novavax(NVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Novavax(NVAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Novavax,NVAX,Novavax股票,Novavax股票老虎,Novavax股票老虎国际,Novavax行情,Novavax股票行情,Novavax股价,Novavax股市,Novavax股票价格,Novavax股票交易,Novavax股票购买,Novavax股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Novavax(NVAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Novavax(NVAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction